CDK4 and breast cancer: Preferences were evaluated in breast cancer patients based on the following characteristics: Patient preferences for chemotherapies used in breast cancer (16), preferences related to trade-offs in adjuvant endocrine therapy for women with estrogen receptor-positive breast cancer (13), the utilization of Conjoint Analysis to evaluate patient preferences for chemotherapy side effects (14), and a DCE exploring preferences among patients, oncologists, and payers for adjuvant endocrine therapy and CDK4/6 inhibitor regimens in early-stage breast cancer (15).